


GLASS Methodology for surveillance of national antimicrobial consumption



GLASS Methodology for surveillance of national antimicrobial consumption





GLASS methodology for surveillance of national antimicrobial consumption

ISBN 978-92-4-001263-9 (electronic version)

ISBN 978-92-4-001264-6 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. GLASS methodology for surveillance of national antimicrobial consumption. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by 400 Communications Limited.

Contents

The GLASS component on surveillance of national antimicrobial Resistance and Use Surveillance System (GLASS) 4 5.2. Data collection 20 2.2. Aim and objectives of GLASS-AMC 4 5.2.1. Collection of AMC data 220 2.2.1. Aim 2.2.2. Objectives 5 5.3. Data submission 21 2.2.2. Objectives 5 5.3. Data submission 21 2.2.3. National level 5 5.3. Data analysis 22 2.3. Regional level 5 5.3. Data analysis 22 2.3. Regional level 5 6 GLASS-AMC 17 platform 24 2.3. Setting up a national surveillance system for AMC 5 6.2. Data submission 24 3 Methodology 8 6.2.1. Data upload 24 3 Methodology 8 6.2.1. Data upload 24 3 Methodology 8 7 AMC 6.2.1. Data upload 24 3 Methodology 8 8 7 AMC data questionnaire 25 3.1. The ATC/DDD system 8 AMC data questionnaire 25 3.2. Measurement issues 8 Annex 1 Introduction to ATC and DDD methodology 28 3.3. The ATC/DDD system 8 Annex 2 List of ATC subgroups under surveillance 35 3.4. Antimicrobials 9 Annex 3 Definition of variables for AMC 35.2. The hospital health care level 10 Annex 4 AMC data questionnaire 45 3.5. Flealth care sectors and levels 10 Annex 5 Specification of the GLASS-AMC product level data file 48 3.6. Flow of antimicrobials 11 Annex 7 Measurement unit list 55 3.6. Potential sources of information on AMC 15 Annex 9 Salt list of DDD for combined products 56 3.6. Annex 1 List of DDD for combined products 56 3.6. Annex 1 List of DDD for combined products 56	Abbreviations		V			Jational reporting	
The GLASS component on surveillance of national antimicrobial Resistance and Use Surveillance System (GLASS) 4 5.2. Data collection 20 20 2.2. Aim and objectives of GLASS-AMC 4 5.2. Data collection 20 20 2.2. Aim and objectives of GLASS-AMC 4 5.2. Data collection 20 20 2.2. Aim and objectives of GLASS-AMC 5.2. WHO template for data collection 21 2.2. Objectives 5 5.3. Data submission 21 5.4. Data analysis 22 2.3. National level 5 5.5. Dissemination of data 22 2.3. Regional level 5 5.5. Dissemination of data 22 2.3. Regional level 5 6 6 6 6 6 6 6 6 6					_		
of national antimicrobial consumption Surveillance System (GLASS) 4 5.2. Data collection 20 2.2. Aim and objectives of GLASS-AMC 2.2.1. Aim 2.2.2. Objectives 2.3. Three-level structure of surveillance of national AMC 2.3.1. National level 2.3.2. Regional level 2.3.3. Global level 2.3.4. Setting up a national surveillance system for AMC 2.4. Setting up a national surveillance system for AMC 3.5. Measurement issues 3.6. Definitions 3.7. Measurement (DDD) 3.8. Antimicrobials 3.9. Health care sectors and levels 3.1. The community health care level 3.3. The community health care level 3.3. Potential sources of information on AMC 3.3. Potential sources of information on AMC 4. Annex 8 Administration route list 4. Data collection for AMC 4. Specification or Amc 5. Data submission 2. Annex 9 Salt list 4. Annex 1 DDD for combined products 5. Annex 9 Salt list 4. Annex 9 Salt list 4. Annex 1 DDD for combined products 5. Annex 9 Salt list 5. Annex 1 DDD for combined products 5. Annex 9 Salt list 5. Annex 9 Salt list 5. Annex 1 DDD for combined products 5. Annex 1 DDD for combined products 5. Annex 9 Salt list 5. Annex 1 DDD for combined products 5. Annex 1 DDD for combined products 5. Annex 9 Salt list 5. Annex 9 Salt list 5. Annex 1 DDD for combined products 5. Annex 2 DDD for combined products 5. Annex 2 DDD for com	1 Introduction		2	4.5.			
Surveillance System (GLASS) 4 5.2. Data collection 20 2.2.1. Aim and objectives of GLASS-AMC 4 5.2.1. Collection of AMC data 20 2.2.2. Discrives 5 5.2. Data submission 21 2.2.2. Data analysis 22 2.3. Three-level structure of surveillance of national AMC 5 5.4. Data analysis 22 2.3. Regional level 5 5.5. Dissemination of data 22 2.3. Global level 5 6 GLASS-AMC IT platform 24 2.3. Setting up a national surveillance system for AMC 6.2.1. Data upload 24 3 Methodology 8 6.2. Data submission 24 4 Data collection of AMC ata questionnaire 25 3.1. The ATC classification 8 8 Annex 1 Introduction to ATC and DDD methodology 28 3.1. The ATC classification 9 Annex 3 Definition of variables for AMC 3.2. Unit of measurement (DDD) 9 under surveillance 37 3.3. The ATC classification 3 4 Annex 3 Definition of variables for AMC 3.5. The hospital health care level 10 Annex 4 AMC data questionnaire 45 3.5. Public and private health care sectors 11 Annex 6 Specification of the GLASS-AMC 11 Annex 8 Administration route list 55 3. Annex 9 Salt list of S	2		4	5	Dat	ta management	20
2.2. Aim and objectives of GLASS-AMC 2.2.1. Aim 3. Aim 4 5.2.2. WHO template for data collection 2.2.2. Objectives 5 5.3. Data submission 2.2.2. Three-level structure of surveillance of national AMC 2.2.3. National level 2.3. Regional level 2.3. Regional level 2.3. Setting up a national surveillance system for AMC 5 6 GLASS-AMC IT platform 2.4 Setting up a national surveillance system for AMC 6 6.2. Data submission 2.4 Setting up a national surveillance system for AMC 6 6.2. Data submission 2.4 Setting up a national surveillance system for AMC 6 6.2. Data submission 2.4 Annex s 2.5 Setting up a national surveillance system for AMC 6 6.2. Data submission 2.4 Annex s 3.1 Definitions 3.2 Measurement issues 3.3 The ATC/DDD system 3.3 The ATC/DDD system 3.3 The ATC classification 3.4 Annex s 3.5 The ATC classification 3.6 Data sources for consumption estimates 3.7 The hospital health care level 3.8 Data submission 3.9 Annex s 4 Annex s 4 Data collection of AMC ata questionnaire 3.0 Annex s 3.1 Definition of ATC and DDD methodology 3.2 List of ATC subgroups under surveillance 3.5 Annex s 3.6 Annex s 3.7 Annex s 3.8 Amc data questionnaire 3.9 Annex s 3.0 Definition of variables for AMC surveillance 3.0 Annex s 3.0 Definition of the GLASS-AMC product level data file 4.0 Annex s 3.0 Annex s 4 A	2.1.			5.1.	Dat	a flow between countries and WHO	20
2.2.1. Aim 4 5.2.2. WHO template for data collection 21 2.2.2. Objectives 5 5.3. Data submission 21 2.3. Three-level structure of surveillance of national AMC 5 5.4. Data analysis 22 2.3. Regional level 5 5.5. Dissemination of data 22 2.3. Regional level 5 6 GLASS-AMC IT platform 24 2.3. Global level 5 6.1. Users 24 2.4 Setting up a national surveillance system for AMC 6 6.2. Data submission 24 2.5. Data submission 24 6.2. Data upload 24 8 6.3. AMC data questionnaire 25 8 Annex 1 Introduction to ATC and DDD methodology 28 3.1. The ATC classification 8 Annex 2 List of ATC subgroups under surveillance 35 3.1. The ATC classification 8 Annex 2 List of ATC subgroups under surveillance 35 3.1. The ATC cassification 8 Annex 2 Definition of variables for AMC surveillance 35 3.1. The ATC cassification 8 Annex 3 Definition of variables for AMC surveillance 35 3.1. The ATC cassification 4 Annex 4 AMC data questionnaire 45 3.2. Measurement (DDD) 9 Annex 3 Definition of variables for AMC surveillance 37 3.5. The hospital health care level 10 Annex 4 AMC data questionnaire 45 3.6. Data sources for consumption estimates 11 Annex 5 Specification of the GLASS-AMC Substance Level Data file 48 3.6. Potential sources of information on AMC 11 Annex 9 Salt list 55 3. Annex 9 Salt list 55 3. Data submission 21 3.4. Data collection for AMC 16 Annex 9 Salt list 55 3. Data submission 6 3.2. Data submission 22 3.4. Data collection for AMC 16 Annex 9 Salt list 55 3. Data submission 6 3.1. Data upload 24 3.2. Data submission 24 4. Annex 9 Salt list 55 3. Data submission 6 3.1. Data upload 24 4. Annex 9 Salt list 55 4. Data collection for AMC 55 4. Data collection for AMC 55 4. Data collection for AMC 55 5. Dissemination of data 52 5.4. Data analysis 22 5.4. Data analysis 6 5.4. Data analysis 5 5.4. Data analysis 5 5.4. Data analysis 5 5.4. Data analysis 52 5.4. Data		-	4	5.2.	Dat	a collection	20
2.2.2. Objectives 5 53. Data submission 21 2.3.1. National level 5 54. Data analysis 22 2.3.2. Regional level 5 55. Dissemination of data 22 2.3.3. Global level 5 6 GLASS-AMC IT platform 24 2.3.3. Global level 6 6.2. Data submission 24 3.3. Methodology 8 6.3. AMC data questionnaire 25 3.1. Definitions 8 7 3.2. Measurement issues 8 7 3.3. The ATC/DDD system 8 7 3.3. The ATC/DDD system 8 7 3.3. The ATC/DDD system 8 7 3.3. The ATC classification 8 7 3.3. Unit of measurement (DDD) 9 8 3.4. Antimicrobials 9 7 3.5. Health care sectors and levels 10 7 3.5. Public and private health care level 10 7 3.6. Data sources for consumption estimates 11 8 3.6. Data collection for AMC 16 4 Data collection for AMC 16 Annex 9 Salt list 4 Annex 9 Salt list 5 Annex 1 Introduction to ATC and DDD methodology 12 3.6. Data sources for combined products 56 Annex 7 Measurement unit list 55 Annex 9 Salt list 55				5.2.1.	Col	lection of AMC data	20
2.3. Three-level structure of surveillance of national AMC 2.3.1. National level 2.3.2. Regional level 2.3.3. Global level 2.4. Setting up a national surveillance system for AMC 2.5. Data analysis 2.6. Dissemination of data 2.7. Data analysis 2.8. Dissemination of data 2.9. Dissemination of data 2.9. Dissemination of data 2.0. Setting up a national surveillance system for AMC 2.1. Data upload 2.2. Data submission 2.3. AMC data questionnaire 2.4. Data analysis 2.5. Dissemination of data 2.6. Data submission 2.7. Data upload 2.8. AMC data questionnaire 2.9. Data analysis 2.0. Data submission 2.4. Data upload 2.5. Data submission 2.6. Data submission 2.7. Data upload 2.8. AMC data questionnaire 2.8. Annex 1 Introduction to ATC and DDDD methodology 2.8. Annex 2 List of ATC subgroups under surveillance 3.9. Definition of ATC and DDD definition of Variables for 3.0. Annex 2 List of ATC subgroups under surveillance 3.1. The ATC classification 3.2. Unit of measurement (DDD) 3.3. The ATC classification 3.4. Antimicrobials 3.5. Health care sectors and levels 3.6. The community health care level 3.7. Annex 2 List of ATC subgroups under surveillance 3.8. Annex 3 Definition of variables for 3.9. Annex 4 AMC data questionnaire 4. Annex 5 Specification of the GLASS-AMC product level data file 4. Annex 6 Specification of the GLASS-AMC Substance Level Data file 3. Annex 7 Measurement unit list 4. Annex 9 Salt list 4. Data collection for AMC 4. Annex 9 Salt list 4. Annex 9 Salt list 4. Annex 9 Salt list 4. Annex 9 DDD for combined products 5. Annex 9 Salt list				5.2.2.		-	21
national AMC 2.3.1. National level 2.3.2. Regional level 2.3.3. Global level 2.4. Setting up a national surveillance system for AMC 2.5. Dissemination of data 2.6. Setting up a national surveillance system for AMC 2.7. Data upload 2.8. Methodology 2.9. Measurement issues 3.1. The ATC/DDD system 3.2. Measurement (DDD) 3.3. The ATC/dDD system 3.3. The ATC/dbd system 3.3. The ATC classification 3.4. Antimicrobials 3.5. Health care sectors and levels 3.6. Data sources for consumption estimates 3.6. Data sources of information on AMC 2.7 Data upload 3.8 Annexes 4.9 Annexes 4.0 Data collection for AMC 2.0 Data submission 3.1 Introduction to ATC and DDD methodology 3.2 List of ATC subgroups 3.3 under surveillance 3.5 Annex 2 List of ATC subgroups 3.6 Annex 3 Definition of variables for 3.7 Annex 4 AMC data questionnaire 3.8 Annex 5 Specification of the GLASS-AMC product level data file 4.0 Data collection for AMC 4.0 Data collection for AMC 4.1 Data collection for AMC 5.5 Dissemination of data 2.2 Dissemination of data 2.4 GLASS-AMC IT platform 2.4 GLASS-AMC IT platform 2.4 Annex 9 Salt list 3.6 GL. Users 3.6 GL. Users 3.7 AMC data questionnaire 3.8 Annex 9 Salt list 3.9 Annex 9 Salt list 3.0 AMC data questionnaire 3.0 Annex 9 Salt list 3.0 Annex 9 Salt list 4.0 Annex 9 Salt list			5	5.3.	Dat	a submission	21
2.3.1. National level 2.3.2. Regional level 2.3.3. Global level 2.4. Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC 8 Setting up a national surveillance system for AMC data questionnaire 8 Setting up a national surveillance system for AMC data questionnaire 8 Setting up a national surveillance system for AMC data questionnaire 8 Setting up a national surveillance system for AMC data questionnaire 8 Setting up a national surveillance system for AMC data questionnaire 8 Setting up a national surveillance system for AMC data questionnaire 8 Setting up a national surveillance system for AMC data questionnaire 9 Annex 2 List of ATC subgroups under surveillance system data for AMC surveillance system for AMC surveillance system for AMC surveillance data file system for AMC surveillance system for AMC surveillance data file system for AMC surveillance for AMC surveillance data file system for AMC surveillance for AMC surveillance for AMC surveillance data file system for AMC surveillance for AMC for AMC surveillance for AMC surveillance for AMC surveillance for AMC for AMC surveillance for AMC for AMC surveillance for AMC surveillance for AMC surveillance for AMC for AMC surveillance for AMC for AMC surveillance for AMC surveillance for AMC surveillance for AMC surv	2.3.		5			-	
2.3.3. Global level 2.4. Setting up a national surveillance system for AMC Methodology 3.1. Definitions 3.2. Measurement issues 3.3. The ATC/DDD system 3.3.1. The ATC classification 3.3.2. Unit of measurement (DDD) 3.4. Antimicrobials 3.5. Health care sectors and levels 3.6. The community health care level 3.7. The hospital health care level 3.7. The hospital health care sectors 3.8. The hospital health care sectors 3.9. The optimized health care sectors 3.10. The optimized health care sectors 3.11. The community health care level 3.12. The hospital health care level 3.3. The optimized health care sectors 3.3. Annex 2 List of ATC subgroups under surveillance 3.5. Health care sectors and levels 3.6. Data sources for consumption estimates 3.6. Data sources for consumption estimates 3.6. Data sources of information on AMC 4 Data collection for AMC 4 Data collection for AMC 5 Secting up a national surveillance 5 Annex 1 Introduction to ATC and DDD methodology 5 Annex 2 List of ATC subgroups under surveillance 5 Annex 3 Definition of variables for AMC surveillance 5 Annex 4 AMC data questionnaire 5 Specification of the GLASS-AMC product level data file 5 Annex 6 Specification of the GLASS-AMC Substance Level Data file 5 Annex 7 Measurement unit list 5 Annex 8 Administration route list 5 Annex 9 Salt list 5 Annex 9 Salt list 5 Annex 9 Salt list 5 Annex 9 Data collection for AMC 5 Annex 1 Data submission 6 A.2. Data upload 6 Annex 1 Introduction to ATC and DDD methodology 8 Annex 2 List of ATC subgroups 1 Annex 2 List of ATC subgroups 1 Annex 3 Definition of variables for 1 Annex 4 AMC data questionnaire 1 Annex 5 Specification of the GLASS-AMC Substance Level Data file 1 Annex 6 Specification of the GLASS-AMC Substance Level Data file 1 Annex 9 Salt list 1 Annex 9 Salt list Annex 9 Salt li	2.3.1.	National level	5	J.J.	D13	Schillation of data	
2.4 Setting up a national surveillance system for AMC Setting up a national surveillance system for AMC Methodology 3.1. Definitions 3.2. Measurement issues 3.3. The ATC/DDD system 3.3.1. The ATC classification 3.4. Antimicrobials 3.5. Health care sectors and levels 3.5.1. The community health care level 3.5.2. The hospital health care level 3.5.3. Public and private health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 4. Data collection for AMC Setting up a national surveillance system 6.2. Data submission 6.2.1. Data upload 6.2.1. Data upload 6.2. AMC data questionnaire 2.4. Annex 1 Introduction to ATC and DDD methodology 2.8. Annex 2 List of ATC subgroups under surveillance 3.9. Annex 3 Definition of variables for AMC surveillance 3.10. Annex 4 AMC data questionnaire 3.11. Annex 5 Specification of the GLASS-AMC product level data file 3.12. Annex 6 Specification of the GLASS-AMC Substance Level Data file 3.13. The community health care level 3.44. Data collection for AMC 3.55. Potential sources of information on AMC 3.66. Data sources of information on AMC 3.67. Annex 9 Salt list 3.68. Amc at a questionnaire 4.00. Annex 2 List of ATC subgroups under surveillance 3.69. Annex 3 Definition of variables for 4. Annex 4 AMC data questionnaire 4. Annex 5 Specification of the GLASS-AMC product level data file 4. Annex 6 Specification of the GLASS-AMC Substance Level Data file 4. Annex 7 Measurement unit list 4. Annex 8 Administration route list 5. Annex 9 Salt list 5. Annex 9 Salt list 5. Annex 9 Salt list of DDD for combined products 5. Annex 9 DDD for combined products 5. Annex 1 Introduction to ATC and 6.2. Data submistration route list 6.2. Data	2.3.2.	Regional level	5	6	GL.	ASS-AMC IT platform	24
Setting up a national surveillance system for AMC 6.2. Data submission 24. 3 Methodology 8. 6.2. Data upload 24. 3. Methodology 8. 6.3. AMC data questionnaire 25. 3.1. Definitions 8. Annexes 3.2. Measurement issues 8. Annex 1 Introduction to ATC and DDD methodology 28. 3.1. The ATC classification 8. Annex 2 List of ATC subgroups under surveillance 36. Antimicrobials 9. Annex 3 Definition of variables for AMC surveillance 37. 35.1. The community health care level 36.2. Data sources for consumption estimates 36. Data sources for consumption estimates 37. 38. Annex 4 AMC data questionnaire 38. Annex 5 Specification of the GLASS-AMC product level data file 48. Annex 6 Specification of the GLASS-AMC Substance Level Data file 49. Annex 7 Measurement unit list 40. Data collection for AMC 40. Data submission 40. 24. 40. Annex 9 Salt list 40. Annex 9 Salt list 41. Annex 9 Salt list 42. Data collection for AMC 40. Annex 9 Salt list 40. Annex 9 Salt list 41. Annex 9 Salt list 42. Data collection for AMC 40. Annex 9 Salt list 41. Annex 9 Salt list 42. Data collection for AMC 43. Annex 9 Salt list 44. Annex 9 Salt list 45. Annex 9 Salt list 46. Annex 9 Salt list 47. Annex 9 Salt list 48. Annex 9 Salt list 49. Annex 9 Salt list 49. Annex 9 Salt list 40. Annex 9 Salt list	2.3.3.	Global level	5				
Methodology 3.1. Definitions 3.2. Measurement issues 3.3. The ATC/DDD system 3.4. Annex 1 Introduction to ATC and DDD methodology 3.5. Unit of measurement (DDD) 3.6. Antimicrobials 3.7. Health care sectors and levels 3.8. Health care sectors and levels 3.9. The community health care level 3.9. The hospital health care sectors 3.0. Data sources for consumption estimates 3.1. The community health care sectors 3.2. Unit of measurement (DDD) 3.3. Annex 2 List of ATC subgroups under surveillance 3.5. Health care sectors and levels 3.6. Annex 3 Definition of variables for 3.6. Annex 4 AMC data questionnaire 3.6. Annex 5 Specification of the GLASS-AMC product level data file 4. Annex 6 Specification of the GLASS-AMC Substance Level Data file 3.6. Data sources of information on AMC 4 Data collection for AMC 5 Data collection for AMC 5 Data collection for AMC 5 Annex 9 Salt list 5 Annex 9 Salt list 5 Annex 10 List of DDD for combined products 5 Annex 10 List of DDD for combined products	2.4						
3.1. Definitions 3.2. Measurement issues 3.3. The ATC/DDD system 3.3.1. The ATC classification 3.3.2. Unit of measurement (DDD) 3.4. Antimicrobials 3.5. Health care sectors and levels 3.6. The community health care level 3.7. The community health care level 3.8. The hospital health care sectors 3.9. Public and private health care sectors 3.0. Data sources for consumption estimates 3.0. Data collection for AMC 3.1. The ATC classification 3.2. Unit of measurement (DDD) 3.3. Annex 2 3.4. Antimicrobials 3.5. Health care sectors and levels 3.6. Data sources for consumption estimates 3.6. Data sources for consumption estimates 3.6. Data collection for AMC 3.6. Data collection for AMC 3.7 Annex 6 3.8 Annex 1 3.8 Annex 2 3.8 Annex 2 3.8 Annex 2 3.8 Annex 3 3.8 Definition of variables for 3.9 Annex 4 3.0 AMC data questionnaire 3.0 Annex 4 3.0 Annex 5 3.0 Annex 5 3.0 Annex 6 3.0 Annex 7 3.0 Annex 7 3.0 Annex 8 3.0 Annex 8 3.0 Annex 9 3.0 Annex 9 3.0 Annex 1 3.0 Annex 1 3.0 Annex 9 3.0 Annex 1 3.0 Annex 1 3.0 Annex 9 3.0 Annex 1 3		for AMC	6				
3.1. Definitions 3.2. Measurement issues 3.3. The ATC/DDD system 3.3. The ATC classification 3.4. Antimicrobials 3.5. Health care sectors and levels 3.6. The community health care level 3.7. The community health care level 3.8. Definition of variables for 3.9. Annex 2 List of ATC subgroups under surveillance 3.9. Annex 3 Definition of variables for 3.9. Annex 4 AMC surveillance 3.9. Annex 4 AMC data questionnaire 3.9. Annex 5 Specification of the GLASS-AMC product level data file 3.9. Data sources for consumption estimates 3.0. Data sources for consumption estimates 3.0. Potential sources of information on AMC 4 Data collection for AMC 4 Data collection for AMC 5 Annex 9 Salt list 5 Annex 10 List of DDD for combined products	2	Wathadalagu	0			=	
3.2. Measurement issues 3.3. The ATC/DDD system 3.3. The ATC classification 3.4. Antimicrobials 3.5. Health care sectors and levels 3.5.1. The community health care level 3.5.2. The hospital health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC 3.7. Annex 10 List of DDD for combined products 4 Annex 2 List of ATC subgroups 3.6. Annex 2 List of ATC subgroups 3.7. Annex 3 Definition of variables for 4 AMC data questionnaire 4 AMC data questionnaire 4 Annex 5 Specification of the GLASS-AMC 4 Potential sources of information on AMC 4 Data collection for AMC 4 Data collection for AMC 5 Annex 9 Salt list 5 Annex 9 Salt list 5 Annex 10 List of DDD for combined products 5 Annex 10 List of DDD for combined products							
33. The ATC/DDD system 33.1. The ATC classification 8 Annex 1 Introduction to ATC and DDD methodology 28 Annex 2 List of ATC subgroups under surveillance 35 Annex 3 Definition of variables for AMC surveillance 37 Annex 4 AMC data questionnaire 37 Annex 5 Specification of the GLASS-AMC product level data file 38 Annex 6 Specification of the GLASS-AMC Substance Level Data file 38 Annex 7 Measurement unit list Annex 8 Administration route list 40 Data collection for AMC 4 Data collection for AMC 4 Data collection for AMC 4 Annex 9 Salt list Annex 9 Salt list Annex 1 Introduction to ATC and DDD methodology 28 Annex 2 List of ATC subgroups under surveillance 37 AMC surveillance 38 Annex 3 Definition of variables for AMC surveillance 39 Annex 4 AMC data questionnaire 40 Annex 5 Specification of the GLASS-AMC Substance Level Data file 40 Specification of the GLASS-AMC Substance Level Data file 41 Annex 7 Measurement unit list Annex 8 Administration route list Annex 9 Salt list Annex 9 Salt list Annex 9 Salt list Annex 10 List of DDD for combined products	_			Anne	xes		27
33.1. The ATC classification 33.2. Unit of measurement (DDD) 3.4. Antimicrobials 3.5. Health care sectors and levels 3.5.1. The community health care level 3.5.2. The hospital health care level 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC 3.7. Annex 2 List of ATC subgroups under surveillance 3.8. Annex 3 Definition of variables for AMC surveillance 3.7. AMC data questionnaire 4.5. Specification of the GLASS-AMC product level data file 4.8. Annex 6 Specification of the GLASS-AMC Substance Level Data file 5.7. Annex 7 Measurement unit list Annex 8 Administration route list 5.8. Annex 9 Salt list Annex 9 Salt list Annex 9 Salt list Annex 10 List of DDD for combined products	_			Anne	x 1	Introduction to ATC and	
3.3.2. Unit of measurement (DDD) 3.4. Antimicrobials 3.5. Health care sectors and levels 3.5.1. The community health care level 3.5.2. The hospital health care level 3.5.3. Public and private health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC 4 Data collection for AMC 3.6. Annex 2 List of ATC subgroups under surveillance 3.7 Annex 3 Definition of variables for AMC surveillance 3.7 Annex 4 AMC data questionnaire 4.5 Annex 5 Specification of the GLASS-AMC product level data file 4.8 Annex 6 Specification of the GLASS-AMC Substance Level Data file 5.7 Annex 7 Measurement unit list Annex 8 Administration route list 5.7 Annex 9 Salt list 5.7 Annex 9 Salt list 5.7 Annex 10 List of DDD for combined products						DDD methodology	28
3.4. Antimicrobials 9 Annex 3 Definition of variables for 3.5. Health care sectors and levels 10 Annex 4 AMC surveillance 37 3.5.1. The community health care level 3.5.2. The hospital health care level 3.5.3. Public and private health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC 4 Data collection for AMC 4 Annex 9 Salt list 5 Annex 10 List of DDD for combined products 5 Annex 10 List of DDD for combined products				Anne	x 2		
3.5. Health care sectors and levels 3.5.1. The community health care level 3.5.2. The hospital health care level 3.5.3. Public and private health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC 3.6. Data collection for AMC 4 Data collection for AMC 3.6. Data sources for consumption estimates 4 Data collection for AMC 4 Data collection for AMC 5 Annex 9 Salt list 5 Annex 10 List of DDD for combined products 5 Annex 10 List of DDD for combined products 5 Annex 10 List of DDD for combined products							35
3.5.1. The community health care level 3.5.2. The hospital health care level 3.5.3. Public and private health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4. Data collection for AMC 4. Data collection for AMC 3.5.1. The community health care level 4. Annex 5 Specification of the GLASS-AMC product level data file 4. Substance Level Data file 5. Annex 7 Measurement unit list 4. Annex 8 Administration route list 5. Annex 9 Salt list 5. Annex 9 Salt list 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products 5. Annex 10 List of DDD for combined products				Anne	x 3		27
3.5.2. The hospital health care level 3.5.3. Public and private health care sectors 3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC 10 Annex 5 Specification of the GLASS-AMC product level data file 4 Annex 6 Specification of the GLASS-AMC Substance Level Data file 5 Annex 7 Measurement unit list 5 Annex 8 Administration route list 5 Annex 9 Salt list 5 Annex 9 Salt list 5 Annex 10 List of DDD for combined products 5 Annex 10 List of DDD for combined products				Anno	s. /		
3.5.3. Public and private health care sectors 10 product level data file 48 3.6. Data sources for consumption estimates 11 Annex 6 Specification of the GLASS-AMC Substance Level Data file 53 3.6.2. Potential sources of information on AMC 11 Annex 7 Measurement unit list 55 4 Data collection for AMC 16 Annex 9 Salt list 55 4 Data collection for AMC 16 Annex 10 List of DDD for combined products 56						_	45
3.6. Data sources for consumption estimates 3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC 4 Data collection for AMC Data collection for AMC 11 Annex 6 Specification of the GLASS-AMC Substance Level Data file Annex 7 Measurement unit list Annex 8 Administration route list Annex 9 Salt list Annex 9 Salt list Annex 10 List of DDD for combined products Annex 10 List of DDD for combined products		-		AIIIIC	ΑЭ		48
3.6.1. Flow of antimicrobials 3.6.2. Potential sources of information on AMC Data collection for AMC Data collection for AMC 11 Substance Level Data file Annex 7 Measurement unit list Annex 8 Administration route list Annex 9 Salt list Annex 9 Substance Level Data file 53 Annex 8 Annex 8 Annex 9 Substance Level Data file 54 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 9 Substance Level Data file 55 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file 55 Annex 8 Annex 9 Substance Level Data file		-		Anne	x 6	-	
3.6.2. Potential sources of information on AMC 11		-					53
Annex 8 Administration route list 55 Annex 9 Salt list 55 Annex 10 List of DDD for combined products 56	_			Anne	x 7	Measurement unit list	55
Annex 10 List of DDD for combined products 56	5.0.2.	1 otential sources of information on Aivic		Anne	x 8	Administration route list	55
Annex 10 List of DDD for combined products 56	/.	Data collection for AMC	16	Anne	x 9	Salt list	55
	4.1.	Elements of data collection	16	Anne	x 10	List of DDD for combined products	56
4.2. AMC data Annex 11 Product origin list 60	•			Anne	X 11	Product origin list	60
4.2.1. Product level data Annex 12 Conversion factor list 60				Anne	x 12	Conversion factor list	60
4.2.2. Substance level data Annex 13 Health care sector list 60			•	Anne	x 13	Health care sector list	60
4.3. Denominator data Annex 14 Health care level list 60	-		-	Anne	x 14	Health care level list	60
4.3.1. Global reporting 17							

Abbreviations

AMC	antimicrobial consumption	
AMR	antimicrobial resistance	
ATC	Anatomical Therapeutic Chemical classification system	
СС	collaborating centre	
DDD	Defined Daily Dose	
DID	Defined Daily Doses/1000 inhabitants/ day	
EphMRA	European Pharmaceutical Market Research Association	
FAO	Food and Agriculture Organization	
GAP-AMR	Global Action Plan on antimicrobial resistance	

GLASS	Global Antimicrobial Resistance and Use Surveillance System
INN	international nonproprietary name
NGO	nongovernmental organization
NFP	national focal point
OIE	World Organisation for Animal Health
отс	over-the-counter
PBIRG	Pharmaceutical Business Intelligence and Research Group
PDD	prescribed daily dose
PIY	packages/1000 inhabitants/year
UN	United Nations
WHO	World Health Organization



1. Introduction

At the Sixty-eighth World Health Assembly held in May 2015, Member States adopted the Global Action Plan on antimicrobial resistance (GAP-AMR). The World Health Assembly urged Member States to implement the action plan, recognizing that this may need to be adapted to specific contexts and national priorities.

The GAP-AMR has five objectives:

- 1. Improve awareness and understanding of antimicrobial resistance.
- 2. Strengthen surveillance and research.
- 3. Reduce the incidence of infection.
- 4. Optimize the use of antimicrobial medicines.
- 5. Ensure sustainable investment in countering antimicrobial resistance.

In Objective 2, surveillance and monitoring are acknowledged as critical components of the response to AMR. In 2015, the World Health Organization (WHO) launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) to:

- improve understanding of the spread and drivers of AMR, including the use of antimicrobial medicines;
- standardize surveillance based on officially recognized data across countries; and
- inform effective control strategies to tackle AMR.

Specifically related to GAP-AMR Objective 4, Member States are requested to provide "stewardship programmes that monitor and promote optimization of antimicrobial use at national and local levels in accordance with international standards in order to ensure the correct choice of medicine at the right dose

- monitor the outcomes of interventions aimed at changing the use of antimicrobials;
- assess the quality of prescribing against practice quidelines;
- raise awareness in health professionals, consumers and policy-makers about the contribution of inappropriate use of antimicrobials in human health to the emergence and spread of antimicrobial resistance.

In 2016, in response to the lack of data on antimicrobial consumption (AMC) in many Member States, especially in low- and middle-income countries, WHO initiated the surveillance of AMC for the collection, analysis and reporting of data on AMC in human health. This included two main components: development of standardized surveillance tools, and support to countries in establishing corresponding national surveillance systems. After developing the methodological tools, WHO rolled out its first cycle of data collection to gather consumption data for the 2014-2016 period in an initial set of countries enrolled in the programme. This first phase included supporting implementation of national surveillance systems in certain low- and middle-income countries. As a result of this pilot phase of data collection, WHO published its first global report and presented data on antimicrobial consumption from 65 countries and areas around the world.1

In 2020, following the pilot phase, the surveillance of AMC became mainstream within GLASS, allowing Member States to report their national AMC data to WHO in a systematic manner. This reporting provides a unique opportunity to access data on both AMC and AMR in a central repository, facilitating the coordinated

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_24863

